6.03
-0.14 (-2.27%)
| Previous Close | 6.17 |
| Open | 6.05 |
| Volume | 4,134,912 |
| Avg. Volume (3M) | 4,380,277 |
| Market Cap | 1,856,824,064 |
| Price / Earnings (Forward) | 49.02 |
| Price / Sales | 3.47 |
| Price / Book | 9.82 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -5.41% |
| Operating Margin (TTM) | -6.35% |
| Diluted EPS (TTM) | -0.090 |
| Quarterly Revenue Growth (YOY) | 13.40% |
| Total Debt/Equity (MRQ) | 229.11% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | 3.56 M |
| Levered Free Cash Flow (TTM) | 29.27 M |
| Return on Assets (TTM) | 3.95% |
| Return on Equity (TTM) | -18.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Amicus Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 1.5 |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.60 |
|
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.75% |
| % Held by Institutions | 102.83% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Palo Alto Investors Lp | 31 Mar 2025 | 7,345,002 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (UBS, 264.84%) | Buy |
| Median | 15.50 (157.05%) | |
| Low | 9.00 (Goldman Sachs, 49.25%) | Hold |
| Average | 15.50 (157.05%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 6.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 02 May 2025 | 9.00 (49.25%) | Hold | 6.67 |
| UBS | 02 May 2025 | 22.00 (264.84%) | Buy | 6.67 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BLEIL LYNN DORSEY | 5.96 | - | 20,414 | 121,667 |
| KELLY MICHAEL AARON | 5.96 | - | 20,414 | 121,667 |
| MCGLYNN MARGARET G | 5.96 | - | 20,414 | 121,667 |
| RAAB MICHAEL | 5.96 | - | 20,414 | 121,667 |
| ROBERTS EIRY | 5.96 | - | 20,414 | 121,667 |
| SBLENDORIO GLENN | 5.96 | - | 20,414 | 121,667 |
| WHEELER CRAIG A | 5.96 | - | 20,414 | 121,667 |
| WHITMAN BURKE W | 5.96 | - | 20,414 | 121,667 |
| Aggregate Net Quantity | 163,312 | |||
| Aggregate Net Value ($) | 973,340 | |||
| Aggregate Avg. Buy ($) | 5.96 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WHITMAN BURKE W | Director | 05 Jun 2025 | Acquired (+) | 20,414 | 5.96 | 121,667 |
| WHEELER CRAIG A | Director | 05 Jun 2025 | Acquired (+) | 20,414 | 5.96 | 121,667 |
| BLEIL LYNN DORSEY | Director | 05 Jun 2025 | Acquired (+) | 20,414 | 5.96 | 121,667 |
| ROBERTS EIRY | Director | 05 Jun 2025 | Acquired (+) | 20,414 | 5.96 | 121,667 |
| KELLY MICHAEL AARON | Director | 05 Jun 2025 | Acquired (+) | 20,414 | 5.96 | 121,667 |
| SBLENDORIO GLENN | Director | 05 Jun 2025 | Acquired (+) | 20,414 | 5.96 | 121,667 |
| RAAB MICHAEL | Director | 05 Jun 2025 | Acquired (+) | 20,414 | 5.96 | 121,667 |
| MCGLYNN MARGARET G | Director | 05 Jun 2025 | Acquired (+) | 20,414 | 5.96 | 121,667 |
| Date | Type | Details |
|---|---|---|
| 03 Jun 2025 | Announcement | New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve |
| 30 May 2025 | Announcement | Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 |
| 07 May 2025 | Announcement | Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference |
| 01 May 2025 | Announcement | Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates |
| 30 Apr 2025 | Announcement | Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States |
| 21 Apr 2025 | Announcement | Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |